Menu

Distribution of World’s First Malaria Vaccine Begins

The World Health Organization and its partners will test the public health effect of immunization in parts of Malawi, Ghana, and Kenya.

Apr 23, 2019
Shawna Williams

ABOVE: © ISTOCK.COM, HAILSHADOW

A program to vaccinate young children in high-risk areas for malaria begins today (April 23) in Malawi, and will soon roll out in Ghana and Kenya, the World Health Organization announced. WHO plans to pilot the use of the vaccine in conjunction with other preventive measures such as mosquito nets and insecticides. 

The immunization requires four doses per child and prevents four in 10 cases of malaria, according to clinical trials.

“This is a bold thing to do, but it’s not a silver bullet,” Thomas Churcher, a malaria expert at Imperial College London, tells the Associated Press. “As long as using the vaccine doesn’t interfere with other efforts, like the urgent need for new insecticides, it is a good thing to do.” 

The vaccine, made by GSK, is the first against a parasite, STAT notes. While its effectiveness is far lower than that of most vaccines, and delivering the required four doses may present logistical challenges, WHO hopes it will boost efforts to combat malaria, which kills 250,000 children each year in Africa alone. “We have seen tremendous gains from bed nets and other measures to control malaria in the last 15 years, but progress has stalled and even reversed in some areas. We need new solutions to get the malaria response back on track, and this vaccine gives us a promising tool to get there,” says WHO Director-General Tedros Adhanom Ghebreyesus in the agency’s statement. “The malaria vaccine has the potential to save tens of thousands of children’s lives.”

The pilot program aims to reach about 360,000 children each year. 

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany.
Microfluidics with a pharma focus<
Microfluidics with a pharma focus<
Microfluidics has rapidly grown in popularity in recent years, and new applications for the technology continue to be reported.
An In-Depth Introduction to Hybridoma-Based Antibody Development
An In-Depth Introduction to Hybridoma-Based Antibody Development
This white paper from GenScript introduces the process of creating hybridomas and using them for monoclonal antibody production.